News
CHMP recommends change to authorisation for Vimpat in partial-onset seizures.- UCB
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Vimpat (lacosamide) from UCB.
The CHMP adopted an extension to an existing indication as follows: Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
Condition: Epilepsy
Type: drug